| Oct 22 |
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
|
| Sep 12 |
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
|
| Sep 12 |
Oncternal plunges on portfolio shakeup
|
| Sep 12 |
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
|
| Aug 11 |
Oncternal Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 10 |
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Oncternal Therapeutics GAAP EPS of -$2.89 beats by $0.14, revenue of $0.8M beats by $0.64M
|
| Aug 8 |
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
|
| Aug 7 |
Oncternal Therapeutics Q2 2024 Earnings Preview
|
| Aug 1 |
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
|
